Teva to acquire Labrys Biologics, Inc.: Novel migraine prophylaxis treatment adds significant new dimension to Teva’s growing pain care franchise
Teva Pharmaceutical Industries Ltd., and Labrys Biologics, Inc., announced that…
4 June 2014 | By Teva
Teva Pharmaceutical Industries Ltd., and Labrys Biologics, Inc., announced that Teva has entered into a definitive agreement to acquire Labrys, broadening Teva’s array of biotechnology assets and capabilities...